Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FPR2 | P25090 | 7/20 | 0.65 |
| ▸ | FPR1 | P21462 | 9/20 | 0.50 |
| ▸ | KDM1A | O60341 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.38 |
| ▸ | MAOA | P21397 | 1/20 | 0.37 |
| ▸ | MAOB | P27338 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18117740 | 1.00 | FPR2 (0.65) | FPR2FPR1KDM1AALDH1A1PDE4B | |
| SCHEMBL19559401 | 1.00 | FPR2 (0.65) | FPR2FPR1KDM1AALDH1A1PDE4B | |
| SCHEMBL16785327 | 1.00 | FPR2 (0.65) | FPR2FPR1KDM1AALDH1A1PDE4B | |
| SCHEMBL29434379 | 0.89 | FPR2 (0.64) | FPR2FPR1KDM1AALDH1A1PDE4B | |
| SCHEMBL18579161 | 0.89 | FPR2 (0.64) | FPR2FPR1KDM1AALDH1A1PDE4B | |
| SCHEMBL18579159 | 0.89 | FPR2 (0.64) | FPR2FPR1KDM1AALDH1A1PDE4B | |
| SCHEMBL18106574 | 0.86 | FPR2 (0.49) | FPR2FPR1KDM1AALDH1A1PDE4B | |
| SCHEMBL22166705 | 0.86 | FPR2 (0.49) | FPR2FPR1KDM1AALDH1A1PDE4B | |
| SCHEMBL20041789 | 0.86 | FPR2 (0.49) | FPR2FPR1KDM1AALDH1A1PDE4B | |
| SCHEMBL18117738 | 0.86 | FPR2 (0.49) | FPR2FPR1KDM1AALDH1A1PDE4B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210107869-A1 | Urea Derivative Or Pharmacologically Acceptable Salt Thereof | KYORIN SEIYAKU KK (JP) | 2021-04-15 | — | — | US | disclosed |
| US-10696630-B2 | Urea derivative or pharmacologically acceptable salt thereof | KYORIN PHARMACEUTICALS CO., LTD. (JP) | 2020-06-30 | — | — | US | disclosed |
| EP-3305763-B1 | DEUTERATED OR ISOTOPICALLY LABELED UREA DERIVATIVES OR PHARMACOLOGICALLY ACCEPTABLE SALTS THEREOF USEFUL AS FPRL-1 AGONISTS | KYORIN SEIYAKU KK (JP) | 2019-07-24 | — | — | EP | disclosed |
| US-10252992-B2 | Urea derivative or pharmacologically acceptable salt thereof | KYORIN PHARMACEUTICAL CO., LTD. (JP) | 2019-04-09 | — | — | US | disclosed |
| EP-3305763-A1 | DEUTERATED OR ISOTOPICALLY LABELED UREA DERIVATIVES OR PHARMACOLOGICALLY ACCEPTABLE SALTS THEREOF USEFUL AS FPRL-1 AGONISTS | Kyorin Pharmaceutical Co., Ltd. (JP) | 2018-04-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10696630-B2 | Urea derivative or pharmacologically acceptable salt thereof | FPR1, FPR2, FPR3 | FPR2 2/4885FPR1 1/4885KDM1A 4486/4885 |
| US-20210107869-A1 | Urea Derivative Or Pharmacologically Acceptable Salt Thereof | FPR1, FPR2, FPR3 | FPR2 2/4885FPR1 1/4885KDM1A 4486/4885 |
| US-10252992-B2 | Urea derivative or pharmacologically acceptable salt thereof | FPR1, FPR2, FPR3 | FPR2 2/4885FPR1 1/4885KDM1A 4486/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.